VALOR STUDY
The VALOR study is a global Phase 3 clinical trial of brepocitinib for adults with dermatomyositis, which recently generated positive results. More details of the results are available here.
CLARITY STUDY
The CLARITY Study is a global Phase 3 clinical trial of brepocitinib for adults with non-anterior non-infectious uveitis (NIU). You can learn more about the CLARITY Study here.
EXPANDED ACCESS POLICY
Priovant is committed to providing medicines that significantly improve quality of life to patients suffering from autoimmune diseases. You can read our Expanded Access Policy here.